Recombinant Anti-CD16 x Anti-CD30 Bispecific Antibody (F(ab')2-scFv2) is designed to be expressed as two chains combined via a hinge region. The scFv of the anti-CD16 specificity is fused to the C terminus of the anti-CD30 Fab fragment, or vice versa. This format comprises four binding sites (two same scFv regions and two same Fab fragments), two for each antigen. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.
Fab-Fc Fusion Proteins
FuncS; Promising therapeutic agent
Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)
FCGR3A; Fc fragment of IgG, low affinity IIIa, receptor (CD16a); CD16; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA; low affinity immunoglobulin gamma Fc region receptor III-A; FcγRIII; FcgammaRIIIA; CD16a antigen; fc-gamma RIII; Fc-gamma RIIIa; Fc-gamma RIII-alpha; igG Fc receptor III-2; Fc gamma receptor III-A; Fc-gamma receptor IIIb (CD16); neutrophil-specific antigen NA; Fc-gamma receptor III-2 (CD 16); immunoglobulin G Fc receptor III; Fc fragment of IgG, low affinity III, receptor for (CD16)
TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email